You think you’re fine. Your family and friends think you’re fine. But, just maybe, you’re not. Maybe you already have ...

The initiative, called Guiding an Improved Dementia Experience, or GUIDE Model, is offered at 327 locations across the U.S., ...

Managed care organizations should evolve cost models to capture savings from dextromethorphan-bupropion’s safety profile, which avoids costly complications associated with traditional Alzheimer ...

Everyone is encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088. You can also contact BioXcel Therapeutics, Inc. at 1-833-201 ...

Andre Yarham of Norfolk, England, was among the youngest people in the U.K. to die from this rare form of dementia.

New safety study links sedative use to increased stroke risk. A large UK study involving more than 165,000 people with dementia has found that the drug risperidone increases the risk of stroke in all ...

"Neumora’s Alzheimer’s disease agitation drug shows early success in Phase Ib trial" was originally created and published by ...

Cognition Therapeutics, Inc. (NASDAQ: CGTX), today announced that a manuscript entitled, “Phase 2 Study of Zervimesine (CT1812) in Participants with Mild-to-Moderate Dementia with Lewy Bodies (DLB)” ...

NMRA-511 showed promising results in Phase 1b study for Alzheimer's disease agitation with favorable tolerability and safety ...

In the elevated anxiety population, NMRA-511 demonstrated a -7.6 and -5.6 placebo-adjusted change from baseline on CMAI total score at Weeks 6 and 8 respectively, representing a Cohen’s d effect size ...

Neumora Therapeutics (NMRA) stock jumps as the company posts early-stage trial data for its experimental drug for Alzheimer’s ...

A case-based, integrative strategy for addressing brain fog, executive dysfunction, and long-term cognitive risk in ...